Duke-NUS Medical School, GenScript Biotech Corporation and Singapore’s Agency for Science, Technology and Research (A*STAR) have announced an exclusive agreement to co-develop and manufacture a serological Covid-19 antibody test that allows rapid detection of neutralising antibodies (NAbs).

NAbs are present in the serum of Covid-19 patients and are responsible for clearing the viral infection.

While there are now many Covid-19 antibody test kits available, this is the first that is capable of measuring NAbs, which usually requires the use of live virus cells, highly skilled operators and complex laboratory procedures that are generally less sensitive and require several days to obtain results.

The new test, known as cPass, can be rapidly conducted within an hour in most research or clinical labs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData